Medtronic plc
MDT Healthcare Medical - Devices NYSE
$90.90
$-2.11 (-2.27%)
Open: $92.49 | High: $92.67 | Low: $90.17 | Prev Close: $93.01
Market Cap: $116.71B
Volume: 10.4M | Avg: 7.8M
Last updated: March 09, 2026 at 02:03 AMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 550
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 25.39 |
| P/B Ratio | 2.38 |
| P/S Ratio | 3.29 |
| EPS | $3.58 |
| Beta | 0.73 |
| Shares Outstanding | 1.28B |
| 52-Week High | $106.33 |
| 52-Week Low | $79.55 |
| SMA 50 | $98.67 |
| SMA 200 | $94.23 |
| Dividend Yield | 3.11% |
| Annual Dividend | $2.83 |
| Next Earnings | May 20, 2026 04:00 AM ET |
Financial Ratios
| Gross Margin | 61.9% |
| Operating Margin | 17.9% |
| Net Margin | 13.0% |
| ROE | 9.5% |
| ROA | 5.0% |
| Debt/Equity | 0.57 |
| Current Ratio | 2.54 |
| Quick Ratio | 2.62 |
Balance Sheet
| Total Assets | $91.68B |
| Total Liabilities | $43.42B |
| Total Equity | $48.02B |
|
|
|
| Cash | $2.22B |
| Total Debt | $28.52B |
| Net Debt | $26.30B |
Income Statement
| Revenue | $33.54B |
| Gross Profit | $21.91B |
| Operating Income | $5.96B |
| Net Income | $4.66B |
|
|
|
| EBITDA | $9.22B |
| Revenue/Share | $27.68 |
Cash Flow
| Operating CF | $7.04B |
| CapEx | $1.86B |
| Free Cash Flow | $5.18B |
|
|
|
| Book Value/Share | $38.37 |
| Tangible Book/Share | $-2.36 |
| Equity/Share | $38.21 |
Technical Indicators
| RSI (14) | 23.78 Oversold |
| MACD |
-1.68
Signal: -0.99
|
| Volatility | 23.71% |
| Trading Signal | Oversold |
Performance & Returns
| 1 Year | +4.52% |
| Sharpe Ratio | 0.18 Fair |
| Volatility (Ann.) | 20.02% Moderate |
| MDT (1Y) | +4.52% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -8.51% |
Sector Comparison (Healthcare)
| Metric | MDT | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 25.39 | 27.7 | 45% |
| P/B Ratio | 2.38 | -19.57 | 36% |
| ROE (%) | 9.54% | -9.47% | 32% |
| Net Margin (%) | 13.00% | 9.25% | 53% |
| Stock Score | 550 | 543.0 | 51% |
| 1Y Return (%) | +4.52 % | +8.21 % | 54% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDT | $90.90 | $94.85 | $95.48 | $96.32 | $98.76 | $94.25 | 23.78 | -1.68 | 23.71% | 2497848 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the MDT stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| MDT | Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
| MDT | Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| MDT | Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care | Neutral | prnewswire.com | Read More |
| MDT | When Fear Spikes, These 5 Quiet, Overlooked Stocks Keep Delivering | Neutral | 247wallst.com | Read More |
| MDT | 2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000 | Neutral | fool.com | Read More |
Recent Insider Trading
No recent insider trading data available for MDT
Company Information
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
| CEO | Geoffrey Straub Martha |
| Employees | 95000 |
| Country | IE |
| IPO Date | 1973-05-02 |
| Exchange | NYSE |
| Website | https://www.medtronic.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category